High concentrations of glucose and/or formation of glucose degradation products (GDPs) during heat sterilization of peritoneal dialysis fluids (PDFs) are believed to be key factors in the limited biocompatibility of PDFs. We have previously shown that several identified GDPs can specifically impair human peritoneal mesothelial cell (HPMC) function. In the present study we aimed at differentiating the respective roles of glucose and GDPs in the toxicity of PDF to mesothelial cells.
♦ Methods
HPMCs were acutely pre-exposed to or incubated chronically in the presence of pH-neutral PDF sterilized by either heat (H-PDF) or filtration (F-PDF). In addition, HPMCs were treated with commercially available H-PDF manufactured either conventionally, that is, in single-chamber containers, or using novel dual-chamber bags that help to substantially decrease GDP formation. Functional assessment of HPMCs included viability, release of interleukin (IL)-6, and proliferation.
♦ Results
Viability and release of IL-6 from HPMCs pretreated with H-PDF (pH 7.3) for 1 to 4 hours were significantly reduced compared to cells exposed to corresponding F-PDF. Incubation in medium mixed (1:1) with H-PDF considerably impaired growth of HPMCs, and over a period of 10 days gradually decreased both the viability of HPMCs and their ability to generate IL-6. These effects were either absent from or significantly less in HPMCs exposed to F-PDF. Similar differences were observed when commercial GDP-containing H-PDFs were compared with newly designed H-PDFs free of GDPs.
♦ Conclusions
Impaired viability and function of HPMCs exposed to glucose-containing pH-neutral PDF is related predominantly to the presence of GDP and, to a significantly lesser extent, to the presence of glucose per se. Prevention of GDP formation during auto-claving markedly improves the biocompatibility of H-PDF with HPMCs.
WilliamsJD, CraigKJ, TopleyN, Von RuhlandC, FallonM, NewmanGR. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol2002; 13:470–9.
2.
DaviesSJ, PhillipsL, NaishPF, RussellGI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol2001; 12:1046–51.
3.
Nilsson ThorellCB, MuscaluN, AndrenAH, KjellstrandPT, WieslanderAP. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int1993; 13:208–13.
4.
WitowskiJ, WisniewskaJ, KorybalskaK, BenderTO, BreborowiczA, GahlGM. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol2001; 12:2434–41.
5.
WitowskiJ, KorybalskaK, WisniewskaJ, BreborowiczA, GahlGM, FreiU. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol2000; 11:729–39.
StylianouE, JennerLA, DaviesM, ColesGA, WilliamsJD. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int1990; 37: 1563–70.
8.
TauerA, KnerrT, NiwaT, SchaubTP, LageC, Passlick–DeetjenJ. In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to Continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun2001; 280: 1408–14.
9.
WitowskiJ, TopleyN, JörresA, LiberekT, ColesGA, WilliamsJD. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int1995; 47:282–93.
10.
WieslanderAP, NordinMK, KjellstrandPT, BobergUC. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int1991; 40:77–9.
11.
TopleyN. What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions?Perit Dial Int1995; 15:205–9.
12.
BreborowiczA, RodelaH, OreopoulosDG. Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int1992; 41:1280–5.
13.
WitowskiJ, KnapowskiJ. Glycerol toxicity for human peritoneal mesothelial cells in culture: comparison with glucose. Int J Artif Organs1994; 17:252–60.
14.
WieslanderAP, KjellstrandPT, RippeB. Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations. Perit Dial Int1995; 15(7 Suppl):S52–9.
15.
BreborowiczA, PolubinskaA, OreopoulosDG. Changes in volume of peritoneal mesothelial cells exposed to osmotic stress. Perit Dial Int1999; 19:119–23.
16.
MatsuokaY, YamauchiA, NakanishiT, SugiuraT, KitamuraH, HorioM. Response to hypertonicity in mesothelial cells: role of Na+/myo-inositol co-transporter. Nephrol Dial Transplant1999; 14:1217–23.
17.
HorioM, YamauchiA, MatsuokaY, MoriyamaT, FukunagaM, ImaiE. Effect of hypertonic stress on amino acid levels and system A activity in rat peritoneal mesothelial cells. Perit Dial Int1999; 19:124–30.
18.
WieslanderAP, DeppischR, SvenssonE, ForsbackG, SpeidelR, RippeB. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Perit Dial Int1995; 15:158–64.
19.
ArbeiterK, BidmonB, EndemannM, BenderTO, EickelbergO, RuffingshoferD. Peritoneal dialysate fluid composition determines heat shock protein expression patterns in human mesothelial cells. Kidney Int2001; 60:1930–7.
20.
RippeB, SimonsenO, HeimbürgerO, ChristenssonA, HaraldssonB, StelinG. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int2001; 59:348–57.
21.
VisserCE, Brouwer SteenbergenJJ, BetjesMG, KoomenGC, BeelenRH, KredietRT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant1995; 10:64–9.
22.
JärklidLE, DeppischR, WieslanderA. Presence of GDP in PD fluids decreases ex vivo mesothelial cell regeneration [Abstract]. Perit Dial Int1999; 19(Suppl 1):S54.
23.
TuncerM, SarikayaM, SezerT, OzcanS, SuleymanlarG, YakupogluG. Chemical peritonitis associated with high dialysate acetaldehyde concentrations. Nephrol Dial Transplant2000; 15:2037–40.
24.
CronauerMV, StadlmannS, KlockerH, AbendsteinB, EderIE, RogatschH. Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1. Am J Pathol1999; 155: 1977–84.
25.
OffnerFA, FeichtingerH, StadlmannS, ObristP, MarthC, KlinglerP. Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am J Pathol1996; 148: 1679–88.
26.
MartinJ, YungS, RobsonRL, SteadmanR, DaviesM. Production and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells. Perit Dial Int2000; 20:524–33.
27.
LambEJ, CattellWR, DawnayAB. In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int1995; 47:1768–74.
28.
HondaK, NittaK, HoritaS, YumuraW, NiheiH, NagaiR. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant1999; 14: 1541–9.
29.
OgataS, YoriokaN, NishidaY, ShaoJC, YamakidoM. Expression of receptor for advanced glycation end product mRNA by human peritoneal mesothelial cells. Nephron2000; 86:245–6.
30.
BoulangerE, WautierMP, WautierJL, BovalB, PanisY, WernertN. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int2002; 61:148–56.
